Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

The Role of the Pharmacist in Health Care: Expanding and Evolving.

Blouin RA, Adams ML.

N C Med J. 2017 May-Jun;78(3):165-167. doi: 10.18043/ncm.78.3.165. No abstract available.

2.

A renaissance in pharmacy education at the University of North Carolina at Chapel Hill.

Roth MT, Mumper RJ, Singleton SF, Lee CR, Rodgers PT, Cox WC, McLaughlin JE, Joyner P, Blouin RA.

N C Med J. 2014 Jan-Feb;75(1):48-52.

3.

A roadmap for educational research in pharmacy.

McLaughlin JE, Dean MJ, Mumper RJ, Blouin RA, Roth MT.

Am J Pharm Educ. 2013 Dec 16;77(10):218. doi: 10.5688/ajpe7710218.

4.

Preparing clinical pharmacy scientists for careers in clinical/translational research: can we meet the challenge?: ACCP Research Affairs Committee Commentary.

Parker RB, Ellingrod V, DiPiro JT, Bauman JL, Blouin RA, Welage LS.

Pharmacotherapy. 2013 Dec;33(12):e337-46. doi: 10.1002/phar.1348. Epub 2013 Sep 30.

PMID:
24114730
5.

Addressing rural health disparities through pharmacy curricula.

Joyner PU, O'Connor SK, Thrasher KA, Blouin RA.

Am J Pharm Educ. 2012 Dec 12;76(10):188. doi: 10.5688/ajpe7610188. No abstract available.

6.

New directions in pharmacy education.

Falcione BA, Joyner PU, Blouin RA, Mumper RJ, Burcher K, Unterwagner W.

J Am Pharm Assoc (2003). 2011 Nov-Dec;51(6):678-82. doi: 10.1331/JAPhA.2011.11545. No abstract available.

PMID:
22068189
7.

Succession planning in US pharmacy schools.

Van Amburgh J, Surratt CK, Green JS, Gallucci RM, Colbert J, Zatopek SL, Blouin RA.

Am J Pharm Educ. 2010 Jun 15;74(5). pii: 86.

8.

Roles of innovation in education delivery.

Blouin RA, Riffee WH, Robinson ET, Beck DE, Green C, Joyner PU, Persky AM, Pollack GM.

Am J Pharm Educ. 2009 Dec 17;73(8):154. Review.

9.

Training clinical pharmaceutical scientists in today's highly competitive times: it's time to commit to change.

Blouin RA, Pollack GM.

Pharmacotherapy. 2009 Feb;29(2):134-6; discussion 136-7. doi: 10.1592/phco.29.2.134. No abstract available.

PMID:
19170583
10.

Preparing for a Renaissance in pharmacy education: the need, opportunity, and capacity for change.

Blouin RA, Joyner PU, Pollack GM.

Am J Pharm Educ. 2008 Apr 15;72(2):42. No abstract available.

11.

Blunted induction of hepatic CYP4A in TNF (p55-/-/p75-/-) double receptor knockout mice following clofibrate treatment.

Van Ess PJ, Poloyac S, Mattson MP, Blouin RA.

Pharm Res. 2002 May;19(5):708-12. No abstract available.

PMID:
12069177
13.

Elevated hepatic and depressed renal cytochrome P450 activity in the Tg2576 transgenic mouse model of Alzheimer's disease.

Van Ess PJ, Pedersen WA, Culmsee C, Mattson MP, Blouin RA.

J Neurochem. 2002 Feb;80(4):571-8.

14.

Cytochrome P450 and antioxidant activity in interleukin-6 knockout mice after induction of the acute-phase response.

Warren GW, van Ess PJ, Watson AM, Mattson MP, Blouin RA.

J Interferon Cytokine Res. 2001 Oct;21(10):821-6.

PMID:
11710994
15.

The effect of endotoxin on hepatocyte nuclear factor 1 nuclear protein binding: potential implications on CYP2E1 expression in the rat.

Roe AL, Poloyac SM, Howard G, Shedlofsky SI, Blouin RA.

J Pharm Pharmacol. 2001 Oct;53(10):1365-71.

PMID:
11697544
16.

2,4,4'-trichlorobiphenyl increases STAT5 transcriptional activity.

Oakley GG, Roe AL, Blouin RA, Twaroski TP, Ganguly TC, Vore M, Lehmler HJ, Robertson LW.

Mol Carcinog. 2001 Apr;30(4):199-208.

PMID:
11346882
17.

Tissue-specific alterations in the 6-hydroxylation of chlorzoxazone following traumatic brain injury in the rat.

Poloyac SM, Perez A, Scheff S, Blouin RA.

Drug Metab Dispos. 2001 Mar;29(3):296-8.

18.

The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans.

Poloyac SM, Tosheva RT, Gardner BM, Shedlofsky SI, Blouin RA.

Clin Pharmacol Ther. 1999 Dec;66(6):554-62.

PMID:
10613610
19.

Effect of recombinant human growth hormone and insulin-like growth factor-1 administration on IGF-1 and IGF-binding protein-3 levels in brain injury.

Rockich KT, Hatton JC, Kryscio RJ, Young BA, Blouin RA.

Pharmacotherapy. 1999 Dec;19(12):1432-6.

PMID:
10600092
20.

The effect of pregnenolone 16alpha-carbonitrile on the pharmacokinetics and metabolism of dapsone in rats.

Lu M, Poloyac SM, McNamara PJ, Blouin RA.

J Pharm Pharmacol. 1999 Jul;51(7):803-10.

PMID:
10467955
21.

Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse.

Watson AM, Poloyac SM, Howard G, Blouin RA.

Drug Metab Dispos. 1999 Jun;27(6):695-700.

22.

Impact of diseases on detoxication.

Blouin RA, Farrell GC, Ioannides C, Renton K, Watlington CO.

J Biochem Mol Toxicol. 1999;13(3-4):215-8. Review. No abstract available.

PMID:
10098907
23.

Hepatic cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/p75) knockout mice after endotoxin administration.

Warren GW, Poloyac SM, Gary DS, Mattson MP, Blouin RA.

J Pharmacol Exp Ther. 1999 Mar;288(3):945-50.

24.

Activities of conjugating and antioxidant enzymes following endotoxin exposure.

Watson AM, Warren G, Howard G, Shedlofsky SI, Blouin RA.

J Biochem Mol Toxicol. 1999;13(2):63-9.

PMID:
9890190
25.

Pharmacokinetic considerations in obesity.

Blouin RA, Warren GW.

J Pharm Sci. 1999 Jan;88(1):1-7. Review. No abstract available.

PMID:
9874695
26.

The effect of high dose endotoxin on CYP3A2 expression in the rat.

Roe AL, Warren G, Hou G, Howard G, Shedlofsky SI, Blouin RA.

Pharm Res. 1998 Oct;15(10):1603-8.

PMID:
9794504
27.
28.

Stability of cephalosporin prodrug esters in human intestinal juice: implications for oral bioavailability.

Stoeckel K, Hofheinz W, Laneury JP, Duchene P, Shedlofsky S, Blouin RA.

Antimicrob Agents Chemother. 1998 Oct;42(10):2602-6.

29.

Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women.

Shedlofsky SI, Israel BC, Tosheva R, Blouin RA.

Br J Clin Pharmacol. 1997 Jun;43(6):627-32.

30.

Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse.

Rees WA, Harkins JD, Woods WE, Blouin RA, Lu M, Fenger C, Holland RE, Chambers TM, Tobin T.

Equine Vet J. 1997 Mar;29(2):104-10.

PMID:
9104558
31.

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry.

Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek QC, Neill JR, Martin WL, Hays LR, Wedlund PJ.

Clin Pharmacol Ther. 1996 Nov;60(5):522-34.

PMID:
8941025
32.

In vivo phenobarbital treatment increases protein binding to a putative AP-1 site in the CYP2B2 promoter.

Roe AL, Blouin RA, Howard G.

Biochem Biophys Res Commun. 1996 Nov 1;228(1):110-4.

PMID:
8912644
33.

Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism.

Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA.

J Clin Invest. 1994 Dec;94(6):2209-14.

34.

Expression of the CYP3A and CYP2C11 enzymes in a nutritionally obese rodent model: response to phenobarbital treatment.

Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA.

Int J Obes Relat Metab Disord. 1994 Jun;18(6):369-74.

PMID:
8081427
35.

Cytochrome P450 2B enzyme induction defect after 2,2',4,4',5,5'-hexachlorobiphenyl treatment in the fa/fa Zucker rat.

Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA.

J Pharmacol Exp Ther. 1994 Mar;268(3):1565-70.

PMID:
8138968
36.

Expression of a male-specific cytochrome P450 isozyme (CYP2C11) in fa/fa Zucker rats: effect of phenobarbital treatment.

Bandyopadhyay AM, Chaudhary I, Robertson LW, Gemzik B, Parkinson A, Blouin RA.

Arch Biochem Biophys. 1993 Dec;307(2):386-90.

PMID:
8274026
37.

Acetaminophen hepatotoxicity: influence of phenobarbital and beta-naphthoflavone treatment in obese and lean Zucker rats.

Tuntaterdtum S, Chaudhary IP, Cibull M, Robertson LW, Blouin RA.

Toxicol Appl Pharmacol. 1993 Dec;123(2):219-25.

PMID:
8248929
38.

Head injury and cytochrome P-450 enzymes. Differential effect on mRNA and protein expression in the Fischer-344 rat.

Toler SM, Young AB, McClain CJ, Shedlofsky SI, Bandyopadhyay AM, Blouin RA.

Drug Metab Dispos. 1993 Nov-Dec;21(6):1064-9.

PMID:
7905385
39.

Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients.

Israel BC, Blouin RA, McIntyre W, Shedlofsky SI.

Br J Clin Pharmacol. 1993 Sep;36(3):229-35.

40.

Cefetamet pivoxil clinical pharmacokinetics.

Blouin RA, Stoeckel K.

Clin Pharmacokinet. 1993 Sep;25(3):172-88. Review.

PMID:
8222459
41.

Effect of nutritional obesity on the induction of CYP2B enzymes following phenobarbital treatment.

Zannikos PN, Bandyopadhyay AM, Robertson LW, Blouin RA.

Drug Metab Dispos. 1993 Sep-Oct;21(5):782-7.

PMID:
7902236
42.

Cytochrome P450 2B enzyme (CYP2B) induction defect following phenobarbital treatment in the fa/fa Zucker rat: molecular characterization.

Blouin RA, Bandyopadhyay AM, Chaudhary I, Robertson LW, Gemzik B, Parkinson A.

Arch Biochem Biophys. 1993 Jun;303(2):313-20.

PMID:
8512318
43.

Effect of genetic obesity and phenobarbital treatment on the hepatic conjugation pathways.

Chaudhary IP, Tuntaterdtum S, McNamara PJ, Robertson LW, Blouin RA.

J Pharmacol Exp Ther. 1993 Jun;265(3):1333-8.

PMID:
8510012
44.

Age and propranolol stereoselective disposition in humans.

Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, DeMaria AN, Wedlund PJ.

Clin Pharmacol Ther. 1992 May;51(5):489-94.

PMID:
1587061
45.

Age and beta-adrenergic receptor sensitivity to S(-)- and R,S(+/-)-propranolol in humans.

Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, DeMaria AN, Wedlund PJ.

Clin Pharmacol Ther. 1992 May;51(5):549-54.

PMID:
1316824
46.

Fleroxacin pharmacokinetics in patients with liver cirrhosis.

Blouin RA, Hamelin BA, Smith DA, Foster TS, John WJ, Welker HA.

Antimicrob Agents Chemother. 1992 Mar;36(3):632-8.

47.

In vivo and in vitro beta 2-adrenergic receptor responsiveness in young and elderly asthmatics.

Hamelin BA, Blouin RA, Wolf KM, Clifton GD, Chandler MH.

Pharmacotherapy. 1992;12(5):376-82.

PMID:
1331993
48.

Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin.

Smith DA, Chandler MH, Shedlofsky SI, Wedlund PJ, Blouin RA.

Br J Clin Pharmacol. 1991 Dec;32(6):735-9.

49.

Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies.

Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ.

Br J Clin Pharmacol. 1991 Mar;31(3):350-2.

50.

Central issues relevant to clinical pharmaceutical scientist training programs.

Blouin RA, Cloyd JC, Ludden TM, Kroboth PD.

Pharmacotherapy. 1991;11(3):257-63. No abstract available.

PMID:
1862017

Supplemental Content

Loading ...
Support Center